Sign inJoin waitlistJoin the waitlist

Kara Landry

Co-Director, Cancer Genetics and Prevention Program · Robert Larner College of Medicine

Credentials: · · · · ·

History

Cancer Genetics and Prevention Program · Robert Larner College of Medicine
Present
Robert Larner College of Medicine
Present

Hematology and Medical Oncology
University of Vermont Medical Center
2018–2021
Internal Medicine
University of Vermont Medical Center
2015–2018
The Robert Larner, M.D. College of Medicine at the University of Vermont
2011–2015

Research

Neuromuscular complications of immune checkpoint inhibitor therapy
Muscle & Nerve · 2018 · 47 citations
Neurological Complications of CAR T Cell Therapy
Review · Current Oncology Reports · 2020 · First of 2 authors · 22 citations
Nivolumab-Induced Thrombotic Thrombocytopenic Purpura in a Patient with Anal Squamous Cell Carcinoma: A Lesson on Hematologic Toxicity from Immunotherapy
Case report · The Oncologist · 2020 · 17 citations

Alissa Thomas
4 papers · 1 as a resident
Neil Zakai
3 papers
DK
Dawn Kleindorfer
2 papers
Janet Ely
2 papers
Marie Wood
2 papers
Mary Cushman
2 papers
Aderonke Adeniyi
1 paper
AN
Amy Noffsinger
1 paper
Bhargavi Pulluri
1 paper
CT
Christopher Trevino
1 paper · 1 as a fellow
DS
David Seward
1 paper
Elvira Umyarova
1 paper

Clinical trials

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2023–2033